Hematology Advisor

Latest

Lisocabtagene Maraleucel Associated With Manageable Toxicities, Deep Responses in Relapsed/Refractory CLL or SLL

Lymphoma Treatment Associated With Impaired Response to COVID-19 Vaccination

Elotuzumab Does Not Improve PFS in Newly Diagnosed Multiple Myeloma

Fourth Dose of BNT162b2 Offers Protection Against Severe COVID-19

Informational Intervention Improves Hemoglobin Levels Among Pregnant Patients With Anemia

Racial Disparities Seen in US Food and Drug Administration Drug Approval Trials in Multiple Myeloma

Relapse Risk Lower With Double CBT Than With Matched Sibling or Unrelated Transplant

Ban of Indoor Tanning Beds Would Reduce Cancers, Cut Costs

Anemia Trends in Reproductive-Age Women in Low- to Middle-Income Countries

Diagnosis and Treatment Progress in PNH

Researchers sought to describe the diagnosis and treatment of patients with rare cases of PNH.

Most Blood Cancer Drug Trials Are Not Randomized, Use Surrogate Endpoints

Of more than 2500 trials analyzed, 21% were randomized.

AHA Outlines Strategies to Improve Nutrition Security in the US

While food insecurity is a leading public health issue, research shows that nutrition security may be a better target for disease prevention strategies.

$FDA approves allogenic CAR T cells targeted at BCMA for phase 1 trial in relapsed/refractory multiple myeloma.$

Addressing Gaps in Care for Patients With Thalassemia

Researchers sought to identify and address gaps in care for patients with thalassemia.

Browse drugs by:

Brand Generic Disease